A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

Published

Journal Article

BACKGROUND & AIMS: Eosinophilic esophagitis is an increasingly recognized disorder with distinctive endoscopic, histologic, and allergic features. Although several therapies are advocated, no placebo-controlled trials have been conducted. We aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinophilic esophagitis. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of swallowed FP in pediatric patients with active eosinophilic esophagitis. Thirty-six patients were randomly assigned to receive either 880 mug of FP (21 patients) or placebo (15 patients) divided twice daily for 3 months. The primary end point was histologic remission, defined by a peak eosinophil count of

Full Text

Duke Authors

Noel, Richard Joseph

Cited Authors

Konikoff, MR; Noel, RJ; Blanchard, C; Kirby, C; Jameson, SC; Buckmeier, BK; Akers, R; Cohen, MB; Collins, MH; Assa'ad, AH; Aceves, SS; Putnam, PE; Rothenberg, ME

Published Date

November 2006

Published In

Gastroenterology

Volume / Issue

131 / 5

Start / End Page

1381 - 1391

PubMed ID

17101314

Pubmed Central ID

17101314

Electronic International Standard Serial Number (EISSN)

1528-0012

International Standard Serial Number (ISSN)

0016-5085

Digital Object Identifier (DOI)

10.1053/j.gastro.2006.08.033

Scholars@Duke